
selective inhibitor of cell cycle and transcriptional cyclin dependent kinases for CDK1/cyclin B, CDK2/cyclin E, and CDK4/cyclin D1. In vivo, R547 showed kinase inhibition profile and the preclinical antitumor activity of R547 for development for use in the treatment of solid tumors. The cyclin-dependent regulators of cell cycle progression. Aberrant expression or altered activity kinase (CDK) complexes leads to escape of cells from cell cycle control,